Respreeza announcement for Europe


Published on June 7th, 2019

Share This Article:


Patients in Europe (Respreeza®) might experience a disruption of Respreeza® in the coming days. Respreeza® is CSL Behring’s prescription drug for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1).

According to CSL Behring, this situation will be resolved in the coming weeks. Only those European countries that receive Respreeza® will be affected.

Respreeza® consists of highly purified alpha-1 antitrypsin derived from human blood plasma and it is a medicine used to slow down the progression of Alpha-1-related lung disease, and it is only available in Europe.

Any information that the Alpha-1 Foundation obtains will be shared with the Alpha-1 Global community.

Share This Article: